Emphysematous pyelonephritis: A review of its pathophysiology and management

Authors

  • Eddy Muñoz Lumbreras Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”
  • José Manuel Michel-Ramírez Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”
  • Michel Gaytán-Murguía Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”
  • José Fernando Gil-García Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”
  • Omar Morales-Ordáz Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”
  • Heriberto Lujano-Pedraza Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”
  • Jorge Antonio Valdéz-Colín Instituto de Salud del Estado de México, Centro Médico “Lic. Adolfo López Mateos”

DOI:

https://doi.org/10.48193/revistamexicanadeurologa.v79i1.390

Keywords:

Emphysematous pyelonephritis, sepsis, outcome factors

Abstract

Emphysematous pyelonephritis is a urologic emergency characterized by an acute necrotizing, perinephric, and parenchymal infection caused by gas-forming uropathogens. It is considered a rare entity, with greater incidence in developing countries. Even though its pathogenesis is not fully understood, there are several well-identified factors involved in the spectrum of elements that result in the production of gas in the renal parenchyma. Various poor outcome factors associated with a high mortality rate have been described in different cohorts. The treatment of those patients can typically be divided into medical management, medical management plus endoscopic or percutaneous drainage, and emergency nephrectomy. Nevertheless, given that there are very few guidelines or treatment algorithms, there is no consensus on the management of patients with emphysematous pyelonephritis.

References

1. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160(6):797-805.

2. Ubee SS, McGlynn L, Fordham M. Emphysematous pyelonephritis. BJU Int. 2011;107(9):1474-8.

3. Wan YL, Lo SK, Bullard MJ, Chang PL, Lee TY. Predictors of outcome in emphysematous pyelonephritis. J Urol. 1998;159(2):369-73.

4. Aswathaman K, Gopalakrishnan G, Gnanaraj L, Chacko NK, Kekre NS, Devasia A. Emphysematous pyelonephritis: outcome of conservative management. Urology. 2008;71(6):1007-9.

5. Kapoor R, Muruganandham K, Gulia AK, Singla M, Agrawal S, Mandhani A, et al. Predictive factors for mortality and need for nephrectomy in patients with emphysematous pyelonephritis. BJU Int. 2010;105(7):986-9.

6. Olvera-Posada D, Armengod-Fischer G, Vázquez-Lavista LG, Maldonado-Ávila M, Rosas-Nava E, Manzanilla-García H, et al. Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology. 2014;83(6):1280-4.

7. Tseng C-C, Wu J-J, Wang M-C, Hor L-I, Ko Y-H, Huang J-J. Host and bacterial virulence factors predisposing to emphysematous pyelonephritis. Am J Kidney Dis Off J Natl Kidney Found. 2005;46(3):432-9.

8. Lin W-R, Chen M, Hsu J-M, Wang C-H. Emphysematous pyelonephritis: patient characteristics and management approach. Urol Int. 2014;93(1):29-33.

9. Kolla PK, Madhav D, Reddy S, Pentyala S, Kumar P, Pathapati RM. Clinical Profile and Outcome of Conservatively Managed Emphysematous Pyelonephritis. ISRN Urol [Internet]. 2012 [citado 2 de abril de 2019];2012. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329657/

10. Peng C-Z, Chen Y-C, How C-K. Emphysematous pyelonephritis with intraperitoneal air dissection. Eur Geriatr Med [Internet]. 2016 [citado 2 de abril de 2019];7(6):589-90. Disponible en: https://www.em-consulte.com/en/article/1097368

11. Hu S-Y, Lee B-J, Tsai C-A, Hsieh M-S. Concurrent emphysematous pyelonephritis, cystitis, and iliopsoas abscess from discitis in a diabetic woman. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2016;51:105-6.

12. Chauhan V, Sharma R. Emphysematous pyelonephritis (class IIIa) managed with antibiotics alone. Hong Kong Med J Xianggang Yi Xue Za Zhi. 2015;21(4):363-5.

13. Crouter AJ, Abraham MK, Wilkerson RG. Emphysematous pyelonephritis in a renal allograft. Am J Emerg Med. 2017;35(3):520.e1-520.e2.

14. Min JW, Lee SK, Ko YM, Kwon KW, Lim JU, Lee YB, et al. Emphysematous pyelonephritis initially presenting as a spontaneous subcapsular hematoma in a diabetic patient. Kidney Res Clin Pract [Internet]. 2014 [citado 2 de abril de 2019];33(3):150-3. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714164/

15. Sodhi KS, Lal A, Vyas S, Verma S, Khandelwal N. Emphysematous pyelonephritis with emphysematous pancreatitis. J Emerg Med. 2010;39(1):e85-87.

16. Olvera-Posada D, García-Mora A, Culebro-García C, Castillejos-Molina R, Sotomayor M, Feria-Bernal G, et al. Factores pronósticos en pielonefritis enfisematosa. Actas Urol Esp [Internet]. 2013 [citado 2 de abril de 2019];37(4):228-32. Disponible en: http://www.elsevier.es/es-revista-actas-urologicas-espanolas-292-articulo-factores-pronosticos-pielonefritis-enfisematosa-S0210480612003269

17. Lu Y-C, Chiang B-J, Pong Y-H, Huang K-H, Hsueh P-R, Huang C-Y, et al. Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis. BMC Infect Dis. 2014;14:418.

18. Khaira A, Gupta A, Rana DS, Gupta A, Bhalla A, Khullar D. Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis. Int Urol Nephrol. 2009;41(4):959-66.

19. Falagas ME, Alexiou VG, Giannopoulou KP, Siempos II. Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol. 2007;178(3 Pt 1):880-5; quiz 1129.

20. Pontin AR, Barnes RD. Current management of emphysematous pyelonephritis. Nat Rev Urol. 2009;6(5):272-9.

21. Fatima R, Jha R, Muthukrishnan J, Gude D, Nath V, Shekhar S, et al. Emphysematous pyelonephritis: A single center study. Indian J Nephrol [Internet]. 2013 [citado 2 de abril de 2019];23(2):119-24. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658289/

22. Tsu JH-L, Chan C-K, Chu RW-H, Law I-C, Kong C-K, Liu P-L, et al. Emphysematous pyelonephritis: an 8-year retrospective review across four acute hospitals. Asian J Surg. 2013;36(3):121-5.

23. Uruc F, Yuksel OH, Sahin A, Urkmez A, Yildirim C, Verit A. Emphysematous pyelonephritis: Our experience in managing these cases. Can Urol Assoc J [Internet]. 2015 [citado 2 de abril de 2019];9(7-8):E480-3. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514496/

24. Lu Y-C, Hong J-H, Chiang B-J, Pong Y-H, Hsueh P-R, Huang C-Y, et al. Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center. Medicine (Baltimore). 2016;95(21):e3573.

25. Bhat RA, Khan I, Khan I, Palla N, Mir T. Emphysematous pyelonephritis: Outcome with conservative management. Indian J Nephrol [Internet]. 2013 [citado 2 de abril de 2019];23(6):444-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841514/

26. Royle J, Williamson R, Strachan M, O’Donnell M, Jackson S, Argryopoulos T, et al. Emphysematous Pyelonephritis Successfully Treated with Laparoscopic Nephrectomy. Br J Med Surg Urol [Internet]. 2009 [citado 2 de abril de 2019];2(5):204-7. Disponible en: https://journals.sagepub.com/doi/abs/10.1016/j.bjmsu.2009.05.004

27. Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N’Dow J, et al. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008;179(5):1844-9.

28. Nana GR, Brodie A, Akhter W, Karim O, Motiwala H. Nephroureterectomy for emphysematous pyelonephritis: An aggressive approach is sometimes necessary. A case report and literature review. Int J Surg Case Rep. 2015;10:179-82.

Downloads

Published

2019-04-08

Issue

Vol. 79 No. 1 (2019): Enero - Febrero

Section

Original articles